On 14 May 2026, the Canadian Food Inspection Agency granted Aurora Cannabis plant breeders' rights over two cannabis cultivars bred at its research facility in Comox, British Columbia. Four months earlier the same company secured Community Plant Variety Rights covering all 27 European Union member states for one of its varieties. Two jurisdictions, one year, the same genetics. Canadian cannabis cultivars have started behaving like registered property.
Cannabis plant breeders' rights are an intellectual property grant that gives the breeder of a new cultivar exclusive control over propagating that variety and over selling, importing or exporting its propagating material. In Canada the Plant Breeders' Rights Act gives that authority to CFIA, and a cannabis variety is protected for 20 years. The European equivalent is a Community plant variety right. For a B2B buyer, the practical question is simpler than the law: who is allowed to grow the plant in your next shipment, and can they prove it?
What plant breeders' rights cover in Canada
Plant breeders' rights work the way a patent works for an invention. A breeder who develops a genuinely new variety gets a fixed period of exclusive commercial control, and everyone else needs permission. CFIA's Plant Breeders' Rights Office administers the system in Canada. Every plant species is eligible except algae, fungi and bacteria, which is why cannabis qualifies at all.
A variety earns protection only if it clears four tests. Examiners call them novelty plus DUS, and UPOV member countries apply the same language:
- New. The variety has not been sold in Canada more than one year before filing, or outside Canada more than four years before filing.
- Distinct. It is measurably different from every variety already known.
- Uniform. It performs consistently from plant to plant.
- Stable. The same characteristics reappear cycle after cycle.
A cannabis grant runs 20 years from the date rights are issued. Through that window the holder decides who may produce, reproduce, sell, import and export the propagating material, and who may licence it onward. Regulations amended in May 2026 raised the term to 25 years for potatoes, asparagus and woody plants. Cannabis was not on that list, so 20 years stands.
What the grant does not do
Three limits matter commercially. The right protects the variety, not the brand, so the trademark on your packaging is a separate filing. It does not protect a cultivation method, a drying protocol or a terpene claim. And the breeders' exemption lets a competitor legally use a protected variety as parent stock to breed something new, provided the result is distinct.
None of that makes the grant weak. It makes it specific. A plant breeders' right is a supply chain control rather than a marketing badge, and it settles who may lawfully propagate the plant your next container is grown from.
Why cultivar rights became an export question in 2026
The sequence tells the story. Aurora was granted EU Community Plant Variety Rights on 20 January 2026 for two Cannabis sativa L. varieties, then Canadian plant breeders' rights on 14 May for two more. Both filings cover cultivars already supplied to medical patients in Germany, Poland, the United Kingdom, Canada and Australia. Nobody spends years of breeding records on varieties they intend to retire.
The commercial pressure sits downstream. Germany imported roughly 67,000 kilograms of medical cannabis in the first quarter of 2026 on BfArM figures, and Canadian product still carries the bulk of that volume. As European importers shift from spot purchases toward multi-year supply and in-market cultivation partnerships, the question of who may legally propagate a named cultivar inside the EU stops being academic. If your German partner wants to grow your genetics locally instead of buying finished flower, someone has to hold the right to authorise it. Entry into the German medical channel increasingly runs through that conversation.
The three frameworks a Canadian LP will meet are not interchangeable:
| Framework | Granting body | Term for cannabis | Territory |
|---|---|---|---|
| Plant breeders' rights | CFIA Plant Breeders' Rights Office | 20 years | Canada only |
| Community plant variety right | CPVO, Angers, France | 25 years | All 27 EU member states |
| Plant variety protection | USDA Plant Variety Protection Office | 20 years, hemp only | United States |
Rights are territorial, and a Canadian grant stops at the border. What UPOV membership buys a Canadian breeder is a priority claim: file at home first, then claim that filing date on a later application in another member country. That is how one variety ends up holding a CFIA grant and a CPVO grant at the same time.
Here is the unhedged version. Any Canadian LP that expects to licence genetics into a European cultivation partner within the next two years should file before the first commercial shipment, not after it. The novelty clock does not wait for a commercial roadmap.
The four-point cultivar rights check for B2B buyers
Most import contracts name a cultivar. Very few say anything about who owns it. If you are buying flower for a regulated medical channel, four questions close that gap before signature.
1. Which name is the legal one
CFIA variety naming rules keep the registered denomination separate from the trademark, so the protected variety and the product on the pharmacy shelf usually carry different names. Aurora's Canadian grant covers SOT20R07-007. The pharmacy shelf says Farm Gas. Ask for both, and confirm the denomination is what appears in the batch record and the import file. Brand names get rebranded. Denominations do not.
2. Granted, or only applied for
A published application is not a grant. Canada allows a six month objection window after an application is published, and a pending file confers no enforceable exclusivity. When a supplier describes its genetics as protected, ask which office issued the right and on what date.
3. Which territories are covered
Confirm the grant reaches the market you are shipping into. A CFIA grant gives no rights in Germany, Australia or Israel. This matters most when an importer intends to sublicence cultivation rather than simply resell finished product.
4. Where the licence chain ends
If the LP grows a variety it did not breed, ask to see the licence and its scope. Some genetics licences permit domestic production but exclude export, and a supply agreement drafted on the opposite assumption creates a problem no certificate of analysis will catch. Put it in the same schedule as the commercial terms you negotiate and the cultivar consistency standards you set.
The Cannabis Act and a Health Canada licence tell you whether a producer may legally grow and export cannabis. Plant breeders' rights tell you whether it may legally grow that particular plant. Those are two different questions, and buyers routinely ask only the first.
Where Canadian LPs actually get stuck
The framework reads cleanly. Qualifying under it is where the work sits, and three obstacles account for most abandoned filings.
The novelty clock has usually already run
A cultivar sold in Canada more than a year before filing is no longer new under the Act. Most Canadian LPs commercialised their strongest phenotypes long before anyone in the building thought about intellectual property, which quietly disqualifies the exact varieties they would most want to protect. Regulations amended in May 2026 helped at the margin by excluding advertising from the definition of sale, so promoting a cultivar before it physically ships no longer starts the clock. Commercial sales still do.
DUS testing needs reference plants, and cannabis is controlled
Distinctness is assessed against reference varieties grown alongside the candidate. For pharmaceutical cannabis that means moving controlled plant material into a testing station under narcotics permits. The CPVO has described that process as demanding enough in time and cost that rights holders hesitate to submit reference varieties at all. European testing authorities have funded work on SNP marker sets to reduce that dependence on side by side trials. Until those tools mature, plan a testing timeline measured in growing cycles rather than weeks.
The filing depends on records the grow team may not keep
Applications run through UPOV PRISMA, the electronic system Canada adopted in 2018, and the Canadian filing fee is a few hundred dollars. That is not the expensive part. The expensive part is evidence: dated phenotype selection data, documented parentage, and proof that the variety performs identically cycle after cycle. Producers who keep those records as routine can file. Producers who select phenotypes by instinct cannot, however good the flower looks. Disciplined cultivar selection for export markets is what makes an application possible in the first place.
AlphaLeaf is a Montreal Licensed Producer of indoor-grown, hand-trimmed cannabis flower built on refined genetics and documented phenotype selection. We hold export authorisation under the Cannabis Act and maintain the ISO/IEC 17025 batch testing and full traceability records that European and Australian medical importers expect from a Canadian supply partner. If you are qualifying genetics for a regulated channel, our team can take your procurement group through the cultivar documentation behind every batch we ship.
Cultivar rights are turning into a procurement question rather than a legal footnote. The genetics in your next shipment belong to somebody. Ask who.
Frequently Asked Questions
Can cannabis get plant breeders' rights in Canada?
Yes. Every plant species except algae, fungi and bacteria is eligible under the Plant Breeders' Rights Act, so Cannabis sativa varieties qualify. CFIA granted rights over two cannabis cultivars in May 2026. A variety must still clear the novelty, distinctness, uniformity and stability tests before rights are issued.
How long do cannabis plant breeders' rights last in Canada?
Twenty years from the date the rights are granted. The longer 25-year term applies to trees and vines, and regulations amended in May 2026 extended it to potatoes, asparagus and woody plants. Cannabis was not included, so 20 years remains the term for cannabis cultivars.
What is the difference between plant breeders' rights and a trademark for a cannabis cultivar?
Plant breeders' rights protect the plant variety itself, controlling who may propagate, sell, import and export its propagating material. A trademark protects the commercial name only. They are separate filings, and CFIA naming rules keep the registered variety denomination distinct from the brand, which is why a protected cultivar usually carries two different names.
Do Canadian plant breeders' rights apply in Germany or the rest of the EU?
No. Plant variety rights are territorial. Protection across the 27 EU member states requires a Community plant variety right from the CPVO in Angers, France, which runs 25 years for cannabis. Because Canada belongs to UPOV, a Canadian filing can support a priority claim on a later EU application.
Can a cultivar that has already been sold still qualify for plant breeders' rights?
Only inside the statutory window. A variety must not have been sold in Canada more than one year before filing, or outside Canada more than four years before filing. Since May 2026, advertising alone no longer counts as a sale for the Canadian novelty test, but a commercial sale does.
What should an importer ask a Canadian LP about cultivar rights?
Ask for the registered variety denomination alongside the brand name, the office that issued the right and the grant date, the territories covered, and the licence chain if the producer did not breed the variety. Confirm that any genetics licence covers export, not domestic production alone.
